Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

18.01 +0.28 (+1.58%)
Streaming Delayed Price Updated: 12:21 PM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 128,196
Open 17.80
Bid (Size) 17.99 (400)
Ask (Size) 18.01 (200)
Prev. Close 17.73
Today's Range 17.79 - 18.20
52wk Range 13.77 - 18.91
Shares Outstanding 353,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
From Bausch + Lomb Corporation
Via Business Wire

Performance

YTD
+8.6%
+8.6%
1 Month
+7.0%
+7.0%
3 Month
+15.1%
+15.1%
6 Month
+5.2%
+5.2%
1 Year
+16.0%
+16.0%

More News

Read More
News headline image
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
From Bausch + Lomb Corporation
Via Business Wire
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down
Via StockStory
News headline image
3 Healthcare Stocks We Steer Clear Of
Via StockStory
News headline image
Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential ↗
Via Benzinga
News headline image
A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q2 Earnings: Bausch + Lomb (NYSE:BLCO) Vs The Rest Of The Pack
Via StockStory
News headline image
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal ↗
Via MarketBeat
News headline image
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
From Bausch + Lomb Corporation
Via Business Wire
News headline image
3 Stocks Under $50 We’re Skeptical Of
Via StockStory
News headline image
Insider Sheds Nearly 53,000 Shares of Consumer Health Stock, Valued at Almost $900,000 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bausch + Lomb (BLCO) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Bausch + Lomb (NYSE:BLCO) Exceeds Q2 CY2026 Expectations
Via StockStory
News headline image
Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons to Avoid BLCO and 1 Stock to Buy Instead
Via StockStory
Topics Stocks
News headline image
Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today
Via StockStory
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
From Bausch + Lomb
Via Business Wire
News headline image
Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care
From Bausch + Lomb
Via Business Wire
News headline image
Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29
From Bausch + Lomb Corporation
Via Business Wire
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Brush Off
Via StockStory
News headline image
New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence
From Bausch + Lomb Corporation
Via Business Wire

Frequently Asked Questions

Is Bausch + Lomb Corporation Common Shares publicly traded?
Yes, Bausch + Lomb Corporation Common Shares is publicly traded.
What exchange does Bausch + Lomb Corporation Common Shares trade on?
Bausch + Lomb Corporation Common Shares trades on the New York Stock Exchange
What is the ticker symbol for Bausch + Lomb Corporation Common Shares?
The ticker symbol for Bausch + Lomb Corporation Common Shares is BLCO on the New York Stock Exchange
What is the current price of Bausch + Lomb Corporation Common Shares?
The current price of Bausch + Lomb Corporation Common Shares is 18.01
When was Bausch + Lomb Corporation Common Shares last traded?
The last trade of Bausch + Lomb Corporation Common Shares was at 09/09/26 12:21 PM ET
What is the market capitalization of Bausch + Lomb Corporation Common Shares?
The market capitalization of Bausch + Lomb Corporation Common Shares is 6.37B
How many shares of Bausch + Lomb Corporation Common Shares are outstanding?
Bausch + Lomb Corporation Common Shares has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.